Present Situation and Prospect of Interventional Therapy for Coronary Heart Disease in China

Mini Review

Austin Cardiol. 2017; 2(1): 1010.

Present Situation and Prospect of Interventional Therapy for Coronary Heart Disease in Chinas

Ma HY, Xing ZP, Liu RL*, Wang SH and Zhao YL

School of Pharmacy, Key Laboratory of Shaanxi Province Craniofacial Precision Medicine Research, Xi’an Jiaotong University, China

*Corresponding author: Rui-Lin Liu, School of Pharmacy, Key Laboratory of Shaanxi Province Craniofacial Precision Medicine Research, Xi’an Jiaotong University, Xi’an, China

Received: September 15, 2017; Accepted: October 18, 2017; Published: October 25, 2017


Coronary heart disease, referred to as CHD, is myocardial dysfunction and organic disease caused by coronary atherosclerosis stenosis and insufficiency of the blood supply, which has seriously affected human health as the deadliest diseases in the world [1]. Results showed that CHD is associated with hyperlipidemia, hypertension, smoking, diabetes, heredity and many other factors [2]. Currently, a variety of methods have been applied to treat the disease all over the world. In this paper, we make a mini review to the current situation of interventional treatment of CHD in China, and point out the existing inadequacies. Hoping to improve the curative effect in the treatment of CHD, we also put forward the corresponding solutions, and predict the future development trend.

Keywords: Coronary heart disease; Interventional therapy; Hypertension


Coronary atherosclerotic heart disease is a heart disease characterized by myocardial ischemia, hypoxia or necrosis, which were caused by stenosis or obstruction of the coronary arteries brought on by atherosclerotic lesions of the coronary arteries, often referred to as CHD. It is the most common cardiovascular disease, with the highest mortality rate in the world. In recent years, the incidence of disease continues to rise, and it is a great threat to human health. WHO divided coronary heart disease into five types, including asymptomatic heart disease, angina pectoris, myocardial infarction, ischemic heart failure and sudden death. Although drug therapy, supportive therapy, surgical treatment and interventional therapy are all used clinically in the treatment of coronary heart disease, interventional therapy is the most widely used and with the best curative effect [3]. The interventional therapy of coronary artery disease is to send the catheter through the radial artery or other artery to the ascending aorta by the way of the carotid artery under the influence of the modern radiology image, and then explore the left or right coronary artery insertion, and then inject a certain amount of contrast agent to develop the coronary artery, with the aim to define the location, extent, and extent of the anatomy deformity and obstruction of the coronary artery, and finally examine and treat the cardiovascular disease [4]. Although interventional therapy has made great progress in the treatment of coronary heart disease, there are still some shortcomings, such as restenosis and a series of complications. If we can clearly understand the mechanism leading to restenosis and reduce the chance of complications by certain measures, interventional therapy will definitely make new achievements in the treatment of coronary heart disease.

Present Situation of Interventional Therapy for Coronary Heart Disease

Historical progress of interventional therapy for coronary heart disease

In 1929, Werner Forssmann, a German surgeon, proposed for the first time that a catheter could be inserted into the heart, which could be used to inject drugs into the heart or measure the blood pressure of the heart. However, it is not accepted because the catheter inserted into the heart may cause sudden death. Werner Forssmann personally tested and demonstrated the safety of the treatment with X rays, but has not been taken seriously yet. It was not until 1941 that two American doctors, Dickinson and Andre F. Cournand, recognized the feasibility of the treatment. Then cardiac catheterization was first applied to the measure of pulmonary arterial pressure and cardiac output, and diagnosis of congenital and rheumatic heart disease, this opened the prelude to cardiovascular interventional therapy. Werner Forssmann also won the Nobel prize for medicine in 1956.

The stage of percutaneous transluminal coronary angioplasty

Percutaneous transluminal coronary angioplasty, also referred to as PTCA (Figure 1), is a therapeutic method used to treat a coronary artery by dilating a narrow or obstructed coronary artery by sending a balloon catheter through percutaneous puncture. In 1964, Dotter, an American doctor, successfully treated a patient with severe embolism of the femoral artery using a home-made balloon catheter. In 1974, the German Andreas Grentzig successfully completed the world’s first case of PTCA. By 1985, Grint Metzger completed 2623 cases of PTCA alone, with the success rate as high as 90%. Since then, PTCA has been widely used in the world. With the improvement of equipment and the improvement of technology, the success rate of PTCA was also rising, and gradually became the most important method for the treatment of coronary artery obstructive disease. However, PTCA still faces a series of problems, such as acute vascular occlusion, low cardiac output syndrome, severe arrhythmia and the rate of restenosis in the middle and late stage is up to 50%. These are mainly because balloon dilate and tear atherosclerotic plaques [5]. The advent of BMS in 1987 overcame the shortcomings of PTCA.

Citation:Ma HY, Xing ZP, Liu RL, Wang SH and Zhao YL. Present Situation and Prospect of Interventional Therapy for Coronary Heart Disease in China. Austin Cardiol. 2017; 2(1): 1010.